Pomalyst

Acquired Immunodeficiency Syndrome, HIV Vaccine, Multiple Myeloma + 2 more
Treatment
4 FDA approvals
17 Active Studies for Pomalyst

What is Pomalyst

PomalidomideThe Generic name of this drug
Treatment SummaryPomalidomide is a medication that helps to modulate the immune system and fight cancerous cells. It is a type of thalidomide and was approved by the FDA in 2013.
Pomalystis the brand name
image of different drug pills on a surface
Pomalyst Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Pomalyst
Pomalidomide
2013
4

Approved as Treatment by the FDA

Pomalidomide, otherwise known as Pomalyst, is approved by the FDA for 4 uses including Multiple Myeloma and Multiple Myeloma .
Multiple Myeloma
Used to treat Trialled at least two prior therapies including lenalidomide and a proteasome inhibitor in combination with Dexamethasone
Multiple Myeloma
Used to treat Multiple Myeloma (MM) in combination with Dexamethasone
Multiple Myeloma (MM)
Used to treat Multiple Myeloma (MM) in combination with Dexamethasone
Trialled at least two prior therapies including lenalidomide and a proteasome inhibitor
Used to treat Trialled at least two prior therapies including lenalidomide and a proteasome inhibitor in combination with Dexamethasone

Effectiveness

How Pomalyst Affects PatientsPomalidomide is much stronger than thalidomide and lenalidomide, being 100 times and 10 times more potent than them, respectively.
How Pomalyst works in the bodyPromalidomide is a drug that helps fight cancer. It stops the growth and death of tumor cells. It also boosts the immune system by aiding T cells and natural killer cells in fighting off infections. Promalidomide works by binding to a specific protein called cereblon, which prevents it from working properly, and also inhibits an enzyme called COX2.

When to interrupt dosage

The advised portion of Pomalyst is contingent upon the specified condition. The dosage fluctuates, in line with the technique of delivery (e.g. Oral or Capsule) noted in the table beneath.
Condition
Dosage
Administration
Multiple Myeloma
, 1.0 mg, 2.0 mg, 3.0 mg, 4.0 mg
, Capsule, Oral, Capsule - Oral
Acquired Immunodeficiency Syndrome
, 1.0 mg, 2.0 mg, 3.0 mg, 4.0 mg
, Capsule, Oral, Capsule - Oral
Kaposi Sarcoma
, 1.0 mg, 2.0 mg, 3.0 mg, 4.0 mg
, Capsule, Oral, Capsule - Oral
HIV Vaccine
, 1.0 mg, 2.0 mg, 3.0 mg, 4.0 mg
, Capsule, Oral, Capsule - Oral
Multiple Myeloma
, 1.0 mg, 2.0 mg, 3.0 mg, 4.0 mg
, Capsule, Oral, Capsule - Oral

Warnings

There are 20 known major drug interactions with Pomalyst.
Common Pomalyst Drug Interactions
Drug Name
Risk Level
Description
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Pomalidomide is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Acteoside
Major
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Acteoside.
Antilymphocyte immunoglobulin (horse)
Major
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Antilymphocyte immunoglobulin (horse).
Azelastine
Major
Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Bacillus calmette-guerin substrain russian BCG-I live antigen
Major
The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Pomalidomide.
Pomalyst Toxicity & Overdose RiskCommon side effects of taking this drug include feeling tired or weak, low levels of white blood cells, low levels of red blood cells, constipation, nausea, diarrhea, difficulty breathing, upper respiratory infections, back pain, and fever.
image of a doctor in a lab doing drug, clinical research

Pomalyst Novel Uses: Which Conditions Have a Clinical Trial Featuring Pomalyst?

17 active trials are currently being conducted to investigate the effectiveness of Pomalyst in managing Refractory Multiple Myeloma.
Condition
Clinical Trials
Trial Phases
Kaposi Sarcoma
8 Actively Recruiting
Phase 1, Phase 2
Multiple Myeloma
6 Actively Recruiting
Phase 1, Phase 2
Multiple Myeloma
0 Actively Recruiting
HIV Vaccine
0 Actively Recruiting
Acquired Immunodeficiency Syndrome
3 Actively Recruiting
Phase 1, Phase 2, Not Applicable

Pomalyst Reviews: What are patients saying about Pomalyst?

5Patient Review
1/15/2020
Pomalyst for Multiple Myeloma
I've been using this treatment since December 2016 for my aggressive myeloma. It's worked much better than Vecade and Cytoxin, and I haven't had a relapse in over three years.
3.7Patient Review
8/14/2015
Pomalyst for Multiple Myeloma
I now have a blood clot in my right lung. I have been on the drug for over a year.
3.3Patient Review
2/22/2018
Pomalyst for Multiple Myeloma
I took this medication for my second outbreak of multiple myeloma, which did help lower my light chains. However, I still developed plasma cytoma in my left arm and had to receive radiation treatment as a result. After trying this again during my maintenance chemotherapy, there was only a temporary lowering of the light chains before they increased 16%. Next month, I'll be trying a different medication.
3.3Patient Review
3/22/2013
Pomalyst for Multiple Myeloma
This medication really irritates my stomach.
2.7Patient Review
6/10/2014
Pomalyst for Multiple Myeloma
The side effects were pretty bad. I developed open lesions inside my vagina and anus.
View All Reviews
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about pomalyst

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Pomalyst a chemo drug?

"Pomalyst is the trade name for the generic chemotherapy drug pomalidomide, which may also be referred to by health care professionals as the generic drug name."

Answered by AI

Is Pomalyst stronger than Revlimid?

"The drug Pomalyst, also known as pomalidomide, is an oral immunomodulatory agent that is similar to Revlimid and Thalomid, but more potent. Pomalyst is manufactured by Celgene."

Answered by AI

What is Pomalyst used for?

"POMALYST, in combination with dexamethasone, is indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies including a proteasome inhibitor and lenalidomide. POMALYST should be used in patients whose disease has progressed on or within 60 days of completion of their last therapy"

Answered by AI

What type of medication is Pomalyst?

"Pomalyst can be prescribed to help treat the symptoms of Multiple myeloma and Kaposi Sarcoma. It may be used on its own or in combination with other medications. Pomalyst is categorised as an Antineoplastic and Angiogenesis Inhibitor drug."

Answered by AI

Clinical Trials for Pomalyst

Have you considered Pomalyst clinical trials? We made a collection of clinical trials featuring Pomalyst, we think they might fit your search criteria.
Have you considered Pomalyst clinical trials? We made a collection of clinical trials featuring Pomalyst, we think they might fit your search criteria.
Have you considered Pomalyst clinical trials? We made a collection of clinical trials featuring Pomalyst, we think they might fit your search criteria.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top